ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)
Status:
Completed
Trial end date:
2018-03-28
Target enrollment:
Participant gender:
Summary
Investigation of the efficacy and safety of triflusal in comparison with aspirin in patients
with stable coronary artery disease (CAD) and in those with a history of an acute
non-cardioembolic ischemic stroke.